Towards a cancer mission in Horizon Europe: recommendations

被引:34
作者
Berns, Anton [1 ,2 ]
Ringborg, Ulrik [2 ,3 ]
Celis, Julio E. [2 ,4 ]
Heitor, Manuel [5 ]
Aaronson, Neil K. [1 ]
Abou-Zeid, Nancy [6 ]
Adami, Hans-Olov [7 ]
Apostolidis, Kathi [8 ]
Baumann, Michael [2 ,9 ]
Bardelli, Alberto [10 ,11 ]
Bernards, Rene [1 ,10 ]
Brandberg, Yvonne [7 ]
Caldas, Carlos [2 ,12 ]
Calvo, Fabien [13 ]
Dive, Caroline [10 ,14 ]
Eggert, Angelika [15 ]
Eggermont, Alexander [2 ,16 ]
Espina, Carolina [17 ,18 ]
Falkenburg, Frederik [19 ]
Foucaud, Jerome [20 ]
Hanahan, Douglas [21 ,22 ]
Helbig, Ulrike [23 ]
Jonsson, Bengt [24 ]
Kalager, Mette [25 ]
Karjalainen, Sakari [26 ]
Kasler, Miklos [27 ]
Kearns, Pamela [28 ,29 ]
Karre, Klas [30 ]
Lacombe, Denis [31 ]
de Lorenzo, Francesco [8 ]
Meunier, Francoise [32 ]
Nettekoven, Gerd [23 ]
Oberst, Simon [12 ,23 ]
Nagy, Peter [33 ,34 ]
Philip, Thierry [33 ,35 ]
Price, Richard [36 ]
Schuz, Joachim [17 ,18 ]
Solary, Eric [6 ,13 ]
Strang, Peter [7 ]
Tabernero, Josep [37 ,38 ]
Voest, Emile [1 ,39 ]
机构
[1] Netherlands Canc Inst, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands
[2] European Acad Canc Sci, Stockholm, Sweden
[3] Karoiinska Univ Hosp, Canc Ctr Karolinska, Bldg R8 01, SE-17176 Stockholm, Sweden
[4] Danish Canc Soc Res Ctr, Strandboulevarden 49, DK-2100 Copenhagen, Denmark
[5] Minist Sci Technol & Higher Educ, Ave Duque DAvila 137, P-1069016 Lisbon, Portugal
[6] Fdn ARC Rech Canc, Villejuif, France
[7] Karoiinska Inst, Stockholm, Sweden
[8] European Canc Patient Coalit, Brussels, Belgium
[9] German Canc Res Ctr, Heidelberg, Germany
[10] European Assoc Canc Res, Nottingham, England
[11] Univ Torino, Dept Oncol, Candiolo, TO, Italy
[12] Canc Res UK Cambridge Ctr, Cambridge, England
[13] Gustave Roussy Canc Campus Grand Paris, Villejuif, France
[14] Univ Manchester, Canc Res UK Manchester Inst, Manchester, Lancs, England
[15] Charite, Berlin, Germany
[16] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands
[17] Int Agcy Res Canc IARC WHO, Lyon, France
[18] Canc Prevent Europe, Lyon, France
[19] Dutch Canc Soc, Amsterdam, Netherlands
[20] French Natl Canc Inst INCa, Boulogne, France
[21] Fed Inst Technol Lausanne EPTL, Swiss Inst Expt Canc Res ISREC, Lausanne, Switzerland
[22] Swiss Canc Ctr Leman SCCL, Lausanne, Switzerland
[23] German Canc Aid, Bonn, Germany
[24] Stockholm Sch Econ, Stockholm, Sweden
[25] Univ Oslo, Inst Hlth & Soc, Oslo, Norway
[26] Assoc European Canc Leagues ECL, Brussels, Belgium
[27] Minist Human Resources, Budapest, Hungary
[28] SIOPE Head Off, Brussels, Belgium
[29] Univ Birmingham, NIHR Birmingham Biomed Res Ctr, Birmingham, W Midlands, England
[30] Swedish Canc Soc, Stockholm, Sweden
[31] EORTC Headquarters, Brussels, Belgium
[32] Federat European Acad Med, Brussels, Belgium
[33] Org European Canc Inst OECI, Brussels, Belgium
[34] Natl Inst Oncol, Budapest, Hungary
[35] Inst Curie, Paris, France
[36] European Canc Org ECCO, Brussels, Belgium
[37] Vall dHebron Univ Hosp, Barcelona, Spain
[38] Inst Oncol VHIO, Barcelona, Spain
[39] Canc Core Europe, Amsterdam, Netherlands
关键词
cancer mission; cancer research; care; prevention continuum; comprehensive cancer centres; European healthcare systems; patient empowerment; science policy; IMMUNE CHECKPOINT INHIBITORS; PALLIATIVE CARE; SOMATIC MUTATIONS; CORE EUROPE; ONCOLOGY; HEALTH; IMMUNOTHERAPY; LANDSCAPE; SURVIVORSHIP; RADIOTHERAPY;
D O I
10.1002/1878-0261.12763
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A comprehensive translational cancer research approach focused on personalized and precision medicine, and covering the entire cancer research-care-prevention continuum has the potential to achieve in 2030 a 10-year cancer-specific survival for 75% of patients diagnosed in European Union (EU) member states with a well-developed healthcare system. Concerted actions across this continuum that spans from basic and preclinical research through clinical and prevention research to outcomes research, along with the establishment of interconnected high-quality infrastructures for translational research, clinical and prevention trials and outcomes research, will ensure that science-driven and social innovations benefit patients and individuals at risk across the EU. European infrastructures involving comprehensive cancer centres (CCCs) and CCC-like entities will provide researchers with access to the required critical mass of patients, biological materials and technological resources and can bridge research with healthcare systems. Here, we prioritize research areas to ensure a balanced research portfolio and provide recommendations for achieving key targets. Meeting these targets will require harmonization of EU and national priorities and policies, improved research coordination at the national, regional and EU level and increasingly efficient and flexible funding mechanisms. Long-term support by the EU and commitment of Member States to specialized schemes are also needed for the establishment and sustainability of trans-border infrastructures and networks. In addition to effectively engaging policymakers, all relevant stakeholders within the entire continuum should consensually inform policy through evidence-based advice.
引用
收藏
页码:1589 / 1615
页数:27
相关论文
共 91 条
[1]   European Academy of Cancer Sciences - position paper [J].
Adami, Hans-Olov ;
Berns, Anton ;
Celis, Julio E. ;
de Vries, Elisabeth ;
Eggermont, Alexander ;
Harris, Adrian ;
zur Hausen, Harald ;
Pelicci, Pier Giuseppe ;
Ringborg, Ulrik .
MOLECULAR ONCOLOGY, 2018, 12 (11) :1829-1837
[2]  
Albreht T, 2017, EUROPEAN GUIDE QUALI, P135
[3]   Signatures of mutational processes in human cancer [J].
Alexandrov, Ludmil B. ;
Nik-Zainal, Serena ;
Wedge, David C. ;
Aparicio, Samuel A. J. R. ;
Behjati, Sam ;
Biankin, Andrew V. ;
Bignell, Graham R. ;
Bolli, Niccolo ;
Borg, Ake ;
Borresen-Dale, Anne-Lise ;
Boyault, Sandrine ;
Burkhardt, Birgit ;
Butler, Adam P. ;
Caldas, Carlos ;
Davies, Helen R. ;
Desmedt, Christine ;
Eils, Roland ;
Eyfjord, Jorunn Erla ;
Foekens, John A. ;
Greaves, Mel ;
Hosoda, Fumie ;
Hutter, Barbara ;
Ilicic, Tomislav ;
Imbeaud, Sandrine ;
Imielinsk, Marcin ;
Jaeger, Natalie ;
Jones, David T. W. ;
Jones, David ;
Knappskog, Stian ;
Kool, Marcel ;
Lakhani, Sunil R. ;
Lopez-Otin, Carlos ;
Martin, Sancha ;
Munshi, Nikhil C. ;
Nakamura, Hiromi ;
Northcott, Paul A. ;
Pajic, Marina ;
Papaemmanuil, Elli ;
Paradiso, Angelo ;
Pearson, John V. ;
Puente, Xose S. ;
Raine, Keiran ;
Ramakrishna, Manasa ;
Richardson, Andrea L. ;
Richter, Julia ;
Rosenstiel, Philip ;
Schlesner, Matthias ;
Schumacher, Ton N. ;
Span, Paul N. ;
Teague, Jon W. .
NATURE, 2013, 500 (7463) :415-+
[4]   Evidence on the Use of Mobile Apps During the Treatment of Breast Cancer: Systematic Review [J].
Almeida Marques Cruz, Flavia Oliveira ;
Vilela, Ricardo Alencar ;
Ferreira, Elaine Barros ;
Melo, Nilce Santos ;
Diniz Dos Reis, Paula Elaine .
JMIR MHEALTH AND UHEALTH, 2019, 7 (08)
[5]   Efficiency and productivity of cancer care in Europe [J].
Althin, Rikard ;
Fare, Rolf ;
Gralen, Katarina ;
Grosskopf, Shawna ;
Jonsson, Bengt ;
Wilking, Nils .
JOURNAL OF CANCER POLICY, 2019, 21
[6]  
[Anonymous], BMJ
[7]   Mammography screening: A major issue in medicine [J].
Autier, Philippe ;
Boniol, Mathieu .
EUROPEAN JOURNAL OF CANCER, 2018, 90 :34-62
[8]   Advances in liquid biopsy approaches for early detection and monitoring of cancer [J].
Babayan, Anna ;
Pantel, Klaus .
GENOME MEDICINE, 2018, 10
[9]   Prevention of Prostate Cancer Morbidity and Mortality Primary Prevention and Early Detection [J].
Barry, Michael J. ;
Simmons, Leigh H. .
MEDICAL CLINICS OF NORTH AMERICA, 2017, 101 (04) :787-+
[10]   Commentary on King-Kallimanis et al.: Inadequate measurement of symptomatic adverse events in immunotherapy registration trials [J].
Basch, Ethan ;
Leahy, Allison Barz .
CLINICAL TRIALS, 2019, 16 (03) :327-328